In a significant step in the increasing market for obesity-related treatments, the US Food and Drug Administration has approved a new weight loss pill from Eli Lilly.
The once-daily drug, Foundayo, provides an alternative to injectable drugs.
When the pill is less effective as Lilly’s weekly injection Zepbound, it may appeal to people looking for a convenient option.
As per the company, Foundayo will be accessible via LillyDirect platform, pharmacies, and telehealth services.
With insurance, some patients may pay as little as $25 every month, while others could pay between $149 and $349 depending on dosage.
The approval comes shortly after competitor Danish drug manufacturer Novo Nordisk launched its own weight loss pill, further intensifying competition in the GLP-1 drug market.
Several studies revealed that Novo Nordisk’s pill leads to increased average weight loss; however, Foundayo provides flexibility, as it can be taken at any time without any conditions.
Experts stated the pill form may attract several new patients who are quite hesitant regarding injections and assist expand the overall obesity treatment market.
Moreover, Eli Lilly plans for a broader launch of the drug, expecting approvals in over 40 countries over the next year.
The launch signals a major shift toward more accessible weight loss treatments, offering patients better choice in managing their health.
Eli Lilly stock
Eli Lilly Stock jumped 4% after receiving FDA's approval of Foundayo weight loss drug.
